We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

88 hedge funds and large institutions have $178M invested in Pacific Biosciences in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more call options, than puts

Call options by funds: $409K | Put options by funds: $331K

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

15% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 26

2% more funds holding

Funds holding: 86 → 88 (+2)

23% less capital invested

Capital invested by funds: $230M → $178M (-$52.9M)

Holders
88
Holders Change
+2
Holders Change %
+2.33%
% of All Funds
2.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
30
Reduced
26
Closed
13
Calls
$409K
Puts
$331K
Net Calls
+$78K
Net Calls Change
+$287K

Top Buyers

Rank Fund Capital Flow
1
MOACM
Mutual of America Capital Management
New York
+$2.17M
2
Goldman Sachs
Goldman Sachs
New York
+$1.68M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$1.19M
4
OIM
Oracle Investment Management
Connecticut
+$1.17M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$889K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.26M
2
Invesco
Invesco
Georgia
-$2.2M
3
BIT
BlackRock Institutional Trust
California
-$2.05M
4
DM
Deerfield Management
New York
-$1.55M
5
IG
ING Group
Netherlands
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$1.06M +$889K +169,984 +365%
BIM
27
Bogle Investment Management
Massachusetts
$1.01M +$501K +95,723 +87%
EIM
28
Essex Investment Management
Massachusetts
$860K -$59K -11,289 -6%
BIM
29
BlackRock Investment Management
Delaware
$825K +$13.6K +2,603 +2%
Deutsche Bank
30
Deutsche Bank
Germany
$766K +$165K +31,506 +25%
AQR Capital Management
31
AQR Capital Management
Connecticut
$746K +$310K +59,200 +64%
CLOS
32
Compagnie Lombard Odier SCmA
Switzerland
$709K +$224K +42,841 +42%
Wellington Management Group
33
Wellington Management Group
Massachusetts
$587K +$290K +55,530 +87%
Jacobs Levy Equity Management
34
Jacobs Levy Equity Management
New Jersey
$542K -$173K -33,090 -23%
WMSA
35
Weiss Multi-Strategy Advisers
New York
$527K +$38.2K +7,300 +7%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$521K +$5.77K +1,103 +1%
Charles Schwab
37
Charles Schwab
California
$421K – – –
TA
38
Teachers Advisors
New York
$410K – – –
AllianceBernstein
39
AllianceBernstein
Tennessee
$378K – – –
NFA
40
Nationwide Fund Advisors
Ohio
$378K +$2.26K +433 +0.6%
GCP
41
GSA Capital Partners
United Kingdom
$313K +$333K +63,660 New
ProShare Advisors
42
ProShare Advisors
Maryland
$291K -$60.6K -11,589 -16%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$268K -$6.8K -1,300 -2%
VOYA Investment Management
44
VOYA Investment Management
Georgia
$253K – – –
SO
45
STRS Ohio
Ohio
$248K +$174K +33,200 +192%
Bank of America
46
Bank of America
North Carolina
$242K +$220K +42,168 +599%
CS
47
Credit Suisse
Switzerland
$230K -$325K -62,166 -57%
DC
48
Deere & Company
Illinois
$220K +$234K +44,806 New
Nomura Holdings
49
Nomura Holdings
Japan
$216K -$200K -38,206 -46%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$209K – – –
1
2
3 4 5

PACB Hedge Fund Activity: Q3 2014 in Review

88 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2014, worth a combined $178M — down 23% from $230M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PACB positions and 13 closed out — a net gain of 2 holders — while 30 added to existing stakes and 26 trimmed.

The largest buyer was Mutual of America Capital Management, opening a new position worth an estimated $2.17M. The largest seller was Millennium Management, cutting an estimated $5.26M.

  • 88 institutional investors held Pacific Biosciences (PACB) as of Q3 2014, up from 86 in Q2 2014.
  • Funds reported $178M of Pacific Biosciences stock for Q3 2014, down 23% quarter-over-quarter.
  • 15 funds opened new Pacific Biosciences positions in Q3 2014 and 13 closed out, a net change of +2 holders.
  • The largest Pacific Biosciences buyer in Q3 2014 was Mutual of America Capital Management, an estimated $2.17M added.
  • The largest Pacific Biosciences seller in Q3 2014 was Millennium Management, an estimated $5.26M sold.

Based on aggregated 13F filings for Q3 2014.